Skip to main content
. 2014 Mar 26;111(12):2516–2524. doi: 10.1152/jn.00882.2013

Table 1.

Demographic data

Neurologically Intact Participants: Experiment I
Participants with Stroke: Experiment II
Characteristics DCS group (n = 19) Placebo group (n = 22) Group differences (P value) DCS group (n = 10) Placebo group (n = 10) Group differences (P value)
Age (means ± SD) 44.6 ± 13.7 43.7 ± 13.7 P = 0.950 55.3 ± 9.6 51.4 ± 11.0 P = 0.429
Gender
    Male 10 15 P = 0.116 7 4 P = 0.398
    Female 9 7 3 6
Race
    Caucasian 4 4 P = 0.655 7 4 P = 0.398
    African  American 15 18 3 6
Dominant side
    Right 15 20 P = 0.033 6 9 P = 0.003
    Left 4 2 4 1
Affected Side
    Right 9 3 P = 0.028
    Left 1 7
Months since stroke (means ± SD) 25 ± 11 21 ± 13 P = 0.727
Stroke location
    Cortical 6 8 P = 0.520
    Subcortical 1 1
    Posterior circulation 1 0
    Unknown 2 1
NIHSS score (median, IQR) 1,2 1,2 P = 0.582
ARAT score (means ± SD) 34 ± 14 41 ± 8 P = 0.148
BBS score (means ± SD) 46 ± 7 47 ± 8 P = 0.561
SB test score (means ± SD) 2.6 ± 2.6 2.8 ± 3.4 P = 0.228

Values are counts except where indicated. DCS, d-cycloserine; IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale: scores for the motor subset range from 0 to 18, with lower scores indicating less impairment; ARAT, Action Research Arm Test: scores range from 0 to 57, with lower scores indicating more impairment; BBS, Berg Balance Scale: scores range from 0 to 56, with lower scores indicating more impairment; SB, Short Blessed Test: scores range from 0 to 28, with lower scores indicating less impairment.